Eli Lilly Q3 Revenue Surges 39% to $24.4 Billion
Eli Lilly reported Q3 2026 revenue of $24.4B, up 39% YoY, exceeding expectations. EPS was $7.48 (adjusted) and $7.22 (GAAP). Mounjaro and Zepbound revenues grew 65% and 48-49% respectively. Foundayo revenue was $184M, below estimates. Full-year revenue guidance raised to $91B–$92B.
How this was made
The 30-second read
Why it matters
The combination of a Q3 beat, strong franchise growth, and a raised full-year revenue range is a direct catalyst for earnings revisions and near-term positioning, while the oral product’s miss adds dispersion to the growth outlook.
Market read
This is a company-specific earnings and guidance update with explicit revenue and EPS figures plus a raised full-year revenue outlook, making it actionable for trading around earnings expectations.
What to watch
The guidance discussion references acquired in-process R&D charges from recent business development deals; traders may focus on whether underlying operating momentum is as strong as headline EPS suggests.
Background
Lilly’s growth is anchored in its injectable GLP-1 portfolio (Mounjaro and Zepbound), with an additional oral GLP-1 candidate (Foundayo) ramping from early quarters.
Ticker impact
Eli Lilly reported Q3 2026 revenue of $24.4B (+39% YoY), beat expectations, and raised full-year revenue guidance to $91B-$92B.
Likely upward pressure as the market reprices full-year growth after the guidance increase, partially offset by the weaker-than-expected Foundayo quarter.
The article provides a fresh earnings/guidance datapoint (revenue, EPS, and raised revenue guidance) tied directly to Lilly’s core products, which typically drives immediate repricing.
Market effects
Reinforces demand strength narrative for GLP-1 obesity/diabetes therapies, supporting sentiment across large-cap pharma and obesity-treatment peers.
US large-cap healthcare sentiment likely improves as investors rotate toward profitable GLP-1 franchise earnings visibility.
Global obesity/diabetes treatment demand expectations may be reinforced, influencing cross-market pharma risk appetite.
Counterpoint
Foundayo’s first full-quarter revenue ($184M) came in below expectations, which could signal competitive or adoption headwinds for oral GLP-1 and limit how far the market extrapolates growth beyond Mounjaro/Zepbound.
Key entities
- companyEli Lilly and Company
Reported Q3 2026 revenue and EPS, with product-level growth and a raised full-year revenue guidance range.
